| Literature DB >> 21054836 |
Abstract
In Japan, attention has increasingly focused on ensuring the quality of care, particularly in the area of cancer care. The 2006 Basic Cancer Control Act reinforced efforts to ensure the quality of cancer care in a number of sectors, including the role of government in ensuring quality. We initiated a government-funded research project to develop quality indicators to measure the quality of care for five major cancers (breast, lung, stomach, colorectal, and liver cancer) in Japan, and palliative care for cancers in general. While we successfully developed a total of 206 quality indicators, a number of issues have been raised regarding the concepts and methodologies used to measure quality. Examples include the choice between measuring the process of care versus the outcome of care; the degree to which the process-outcome link should be confirmed in real-world measurement; handling of exceptional cases; interpretation of measurement results between quality of care versus quality of documentation; creation of summary scores; and the optimal number of quality indicators for measurement considering the trade-off between the measurement validity versus resource limitations. These and other issues must be carefully considered when attempting to measure quality of care, and although many appear to have no correct answer, continuation of the project requires that a decision nevertheless be made. Future activities in this project, which is still ongoing, should focus on the further exploration of these problems.Entities:
Year: 2010 PMID: 21054836 PMCID: PMC2990721 DOI: 10.1186/1751-0759-4-14
Source DB: PubMed Journal: Biopsychosoc Med ISSN: 1751-0759
Example of quality indicators developed in our project
| Denominator (target patients) | Numerator (care processes indicated) |
|---|---|
| Patients with stage 3 colorectal cancer who have undergone surgical resection | Patients who have received standard chemotherapy within 8 weeks of surgery or who have reasons for not receiving chemotherapy |
| Patients with colorectal cancer who have undergone surgical resection | Patients who have received total colonoscopy or who have reasons for not receiving total colonoscopy |
| Patients with gastric cancer who have undergone endoscopic resection and have one of the following: | Patients who have received surgical treatment with lymph-node dissection |
| Patients diagnosed with breast cancer | Patients who have had their Her-2/neu status examined |
| Patients receiving treatment for liver cancer | Patients who have had the levels of α-fetoprotein and protein in vitamin K absence-II checked before the start of therapy |
| Patient with lung cancer who have undergone surgical resection or radiation therapy on their lungs | Patients whose lung function has been assessed via spirometry |
| Patient receiving narcotic analgesics | Patients who have received education or medication to prevent constipation |